Open AccessJournal Article
Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE.
Huang Wukui,You Lina,Yang Shufa,Liu Dengyao,Mo Liu,Hailin Wang,Pingju Wang,Pahaerding Baikere,Gu Peng,Abulajiang Abulikemu,Shaoha Yuan,Fan Xiwen +11 more
TLDR
It was shown that metronomic S-1 chemotherapy plus TACE may be a promising treatment of BCLC Stage B HCC refractory to TACE and associated with a better but not statistically significant TTP, RR and OS.Abstract:
Purpose To assess the efficacy and safety of metronomic S-1 chemotherapy combination with transcatheter arterial chemoembolization (TACE) for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B hepatocellular carcinoma (HCC) refractory to TACE. Methods Twenty six patients met the eligibility criteria and were enrolled. TACE was performed on day 1, and metronomic S-1 chemotherapy on days 2-15. Tumor assessment was performed one month later. The primary endpoints were time to progression (TTP) and adverse events (AE). Results Twenty six patients in total received 176 TACE interventions. There were 101 TACE interventions in 15 patients of metronomic S-1 chemotherapy plus TACE (TS) and 75 in 11 patients of TACE monotherapy (TM). Fifteen TS patients received a total of 55 cycles of treatment with S-1, with a median of 4 cycles (range 2-6). The total dose of S-1 was 6165 mg per day in 15 patients (average 120 mg, range 100-125). Median TTP and overall survival (OS) of TS group were 6 months (95% CI, 4.7-7.3) and 17 months (95% CI, 15.6-18.4), respectively, while for the TM group were 4 months (95% CI, 2.4-5.6) and 15 months (95% CI, 9.2-20.8), respectively. Though there were higher tumor response rate (RR) and disease control rates (DCRs) in patients with TS, no significant differences were detected. Both treatment approaches were tolerable with low grade AE. Conclusions In the present study, metronomic S-1 chemotherapy plus TACE in the present study was tolerable and associated with a better but not statistically significant TTP, RR and OS. It showed that metronomic S-1 chemotherapy plus TACE may be a promising treatment of BCLC Stage B HCC refractory to TACE.read more
Citations
More filters
Journal ArticleDOI
Recent advances in hepatocellular carcinoma therapy
Rinku Dutta,Ram I. Mahato +1 more
TL;DR: The pathogenesis of HCC is discussed in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides, with a broad overview of the pathogenic of the disease and treatment efficacy.
Journal ArticleDOI
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Peisi Kou,Yan Zhang,Wenbo Shao,Hui Zhu,Jingze Zhang,Haiyong Wang,Li Kong,Jinming Yu,Jinming Yu,Jinming Yu +9 more
TL;DR: One patient with advanced hepatocellular carcinoma, who received apatinib combined with transhepatic arterial chemotherapy and embolization, and chemotherapy respectively, was confirmed as partial response by the Response Evaluation Criteria in Solid Tumors (RECIST), indicating that apatin ib may be a superior choice for HCC patients.
Journal ArticleDOI
Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer
TL;DR: As there is a lack of well-conducted, randomized clinical trials evaluating the role of metronomic chemotherapy in esophagogastric cancer, it cannot be recommended as the standard of care; however, it can be considered to be a therapeutic option, especially in elderly patients with relapsed disease for whom other therapeutic options are limited.
Journal ArticleDOI
Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence
TL;DR: Mainly based on evidence from two retrospective studies conducted in Japan, sorafenib is recommended as the first choice for subsequent treatment after TACE failure/refractoriness.
References
More filters
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Journal ArticleDOI
Management of hepatocellular carcinoma.
Jordi Bruix,Morris Sherman +1 more
TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Jordi Bruix,Morris Sherman,Josep M. Llovet,Michel Beaugrand,Riccardo Lencioni,Andrew K. Burroughs,Erik Christensen,Luigi Pagliaro,Massimo Colombo,Juan Rodés +9 more
Journal ArticleDOI
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Josep M. Llovet,Maria Isabel Real,Xavier Montaña,Ramon Planas,Susana Coll,John J. Aponte,Carmen Ayuso,Margarita Sala,Jordi Muchart,Ricard Solà,Joan Rodés,Jordi Bruix +11 more
TL;DR: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma and was associated with a significantly lower rate of portal-vein invasion than conservative treatment.